Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Received Date † | December 22, 2000 | ||||||||
Last Updated Date | October 6, 2008 | ||||||||
Start Date † | December 2000 | ||||||||
Current Primary Outcome Measures † |
Reduction in proteinuria in recurrent FSGS following renal transplant with plasma exchange and cyclophosphamide. [ Time Frame: every 3 months up to a year ] [ Designated as safety issue: No ] | ||||||||
Original Primary Outcome Measures † | Same as current | ||||||||
Change History | Complete list of historical versions of study NCT00007475 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures † | |||||||||
Original Secondary Outcome Measures † | |||||||||
Descriptive Information | |||||||||
Brief Title † | Permeability Factor Protein in Focal Segmental Glomerulosclerosis | ||||||||
Official Title † | Permeability Factor in Focal Segmental Glomerulosclerosis | ||||||||
Brief Summary | The purpose of this study is to learn more about permeability factor-a protein found in some patients with a kidney disease called focal segmental glomerulosclerosis (FSGS). Patients with FSGS have proteinuria (excessive protein excretion in the urine) and glomerulosclerosis (scarring in the filtering part of their kidney called the glomerulus). The cause of FSGS is not known. It may be treated with various medicines, including steroids, cyclosporine and cyclophosphamide. Patients with high levels of permeability factor may be more likely to have a recurrence of FSGS after kidney transplant, damaging the transplanted kidney. Patients 18 years of age and older with FSGS may be eligible for this study, including those 1) who have not been treated; 2) who require steroids to prevent a return of proteinuria; 3) whose proteinuria did not respond to steroid treatment; 4) who had a recurrence of FSGS after having a kidney transplant; and 5) who are on dialysis and are considering kidney transplantation. All study participants will have 1 teaspoon of blood drawn to measure permeability factor and perform other tests related to FSGS. Additional samples may be requested if levels of the protein are very low or very high. Patients who have recurrent FSGS following a kidney transplant may choose to 1) continue on their present immunosuppressive drugs; 2) try to treat the FSGS directly with plasma exchange; or 3) try to treat the FSGS directly with plasma exchange plus cyclophosphamide, an immune-suppressing medicine. Plasma exchange is the removal of plasma (the fluid part of the blood) and replacement with a human albumin solution. This procedure may effectively remove the permeability factor from the plasma of patients with FSGS. Plasma exchange is done by a procedure called apheresis. In this procedure, whole blood is drawn through a needle in the forearm or by another method, the plasma is separated from the blood cells and removed, and the cells are returned to the patient through a second needle. Plasma exchange usually requires four to six apheresis procedures, each lasting about 2 hours. Cyclophosphamide, which is approved to treat some leukemias, is also commonly used for FSGS. This drug might lower production of permeability factor, thereby reducing kidney damage. Patients with good kidney function will take standard doses of cyclophosphamide by mouth for 3 months. Patients with impaired kidney function will receive 75 percent of the ... |
||||||||
Detailed Description | Focal segmental glomerulosclerosis (FSGS) is a renal syndrome characterized by proteinuria (usually nephrotic range), limited response to conventional therapy, and a poor renal prognosis, with progression to end stage renal failure in at least 50% of patients. As a syndrome, FSGS likely has many specific etiologies, only a few of which are well-defined. Recently, it has been suggested that some idiopathic FSGS patients have elevated circulating levels of a protein that induces glomerular permeability in vitro and in vivo. While there has been no consistent term for this factor, it will be termed here FSGS permeability factor (FPF). The purposes of the present study are five fold:
Patient participation is divided into an evaluation phase, in which FPF levels, RNA expression profiles, and patient eligibility for participation in treatment protocols are determined, and a treatment phase in which specific immunomodulatory therapy is introduced in an open label fashion. We propose to define carefully the relationship between elevated FPF and remission of proteinuria in patients with FSGS in native kidneys, following treatment with standard therapies (daily prednisone, cyclophosphamide) and experimental therapies (pulse dexamethasone, pirfenidone). In patients with recurrent FSGS in renal allografts, we will determine the kinetics of FPF following plasma exchange and following plasma exchange plus cyclophosphamide. In patients with elevated FPF levels who are awaiting renal transplantation, we will determine the kinetics of FPF following plasma exchange and following plasma exchange plus cyclophosphamide, and examine the rate of recurrent FSGS in these patients. |
||||||||
Study Phase | Phase II | ||||||||
Study Type † | Interventional | ||||||||
Study Design † | Treatment, Open Label, Single Group Assignment, Efficacy Study | ||||||||
Condition † | Focal Glomerulosclerosis | ||||||||
Intervention † |
|
||||||||
Study Arms / Comparison Groups | |||||||||
Publications * |
|
||||||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status † | Recruiting | ||||||||
Enrollment † | 180 | ||||||||
Completion Date | |||||||||
Primary Completion Date | |||||||||
Eligibility Criteria † |
EXCLUSION CRITERIA:
A) Allergy or hypersensitivity to cyclophosphamide B) Leukocyte less than 3000 cells/microliter or ANC less than 1500 cells/microliter or evidence of bone marrow compromise C) Prior irradiation to the heart or therapy with doxorubicin or other cardiotoxic medication (may increase the risk for cardiotoxicity) D) Peritoneal dialysis, as there is no published evidence that cyclophosphamide metabolites can be safely removed. E) Certain drugs will be used with caution or avoided. Barbiturates and phenytoin induce the hepatic enzymes that metabolize cyclophosphamide and therefore if these medications are required, cyclophosphamide doses may need to be increased to achieve a comparable immunosuppressive effect. Drugs that inhibit cyclophosphamide metabolism include allopurinol, imipramine, and phenothiazines, chloramphenicol and chlorpromazine; these drugs will be avoided. NSAID increase the risk of hyponatremia; these drugs will be avoided. |
||||||||
Gender | Both | ||||||||
Ages | 18 Years and older | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts †† |
|
||||||||
Location Countries † | United States | ||||||||
Expanded Access Status | |||||||||
Administrative Information | |||||||||
NCT ID † | NCT00007475 | ||||||||
Responsible Party | Jeffrey B. Kopp, M.D./National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health | ||||||||
Secondary IDs †† | 01-DK-0053 | ||||||||
Study Sponsor † | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | ||||||||
Collaborators †† | |||||||||
Investigators † | |||||||||
Information Provided By | National Institutes of Health Clinical Center (CC) | ||||||||
Verification Date | August 2008 | ||||||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |